{"id":405458,"date":"2020-12-24T05:03:33","date_gmt":"2020-12-24T10:03:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405458"},"modified":"2020-12-24T05:03:33","modified_gmt":"2020-12-24T10:03:33","slug":"foresee-pharmaceuticals-announces-completion-of-us47-million-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/","title":{"rendered":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TAIPEI<\/span>, Dec.\u00a024, 2020 \/PRNewswire\/ — Foresee pharmaceuticals (TPEx: 6576.TWO) (“Foresee”) announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88<\/span> per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million<\/span> (NT$1.32 billion<\/span>).<\/p>\n

The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee’s existing drug research and development programs \u2013 such as FP-025, for which a Phase II\/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. <\/p>\n

In addition to the progress of FP-025, Foresee’s Camcevi\u2122 42 mg, a ready-to-use 6-month depot formulation of leuprolide mesylate, is currently under review process by the FDA and EMA, which will soon be followed by Camcevi\u2122 3-month depot; FP-045, an orally bioavailable ALDH2 activator, which previously obtained permission from the FDA to proceed with the clinical study, is planned to enter into a Phase 1\/2 dose-finding study in adolescent and pediatric patients with Fanconi anemia. <\/p>\n

Previously this year, Foresee has completed a round of private placement financing, raising approximately US$3 million<\/span> (NT$90 million<\/span>) by the issuance of 1,200,000 shares of common stock at a price of NT$75<\/span>. <\/p>\n

\n About Foresee Pharmaceuticals Co., Ltd.<\/b>\n <\/p>\n

Foresee is a Taiwan<\/span> and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.<\/p>\n

Foresee’s product portfolio includes late stage and early stage programs such as FP-001, 6-month and 3-month, stable, ready-to-use versions of leuprolide mesylate for injection, for which regulatory approval reviews are currently underway in US and EU for the 6-month product and regulatory submissions for 3-month product are in preparation; FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a Phase 2 proof-of-concept study, and target to initiate Phase 2 study for COVID-19 virus induced acute respiratory distress syndrome (ARDS); FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b<\/span>\/2 study is currently planned for Fanconi Anemia, and FP-004, a novel, subcutaneously injectable product in development for the treatment of opioid use disorder and pain. www.foreseepharma.com<\/a><\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing-301198388.html<\/a><\/p>\n

SOURCE Foresee Pharmaceuticals Co., Ltd.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire TAIPEI, Dec.\u00a024, 2020 \/PRNewswire\/ — Foresee pharmaceuticals (TPEx: 6576.TWO) (“Foresee”) announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million (NT$1.32 billion). The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee’s existing drug research and development programs \u2013 such as FP-025, for which a Phase II\/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. In addition to the progress of FP-025, Foresee’s Camcevi\u2122 42 mg, a … <\/p>\n

Continue reading “Foresee Pharmaceuticals Announces Completion of US$47 Million Financing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405458","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nForesee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TAIPEI, Dec.\u00a024, 2020 \/PRNewswire\/ — Foresee pharmaceuticals (TPEx: 6576.TWO) (“Foresee”) announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million (NT$1.32 billion). The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee’s existing drug research and development programs \u2013 such as FP-025, for which a Phase II\/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. In addition to the progress of FP-025, Foresee’s Camcevi\u2122 42 mg, a … Continue reading "Foresee Pharmaceuticals Announces Completion of US$47 Million Financing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-24T10:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing\",\"datePublished\":\"2020-12-24T10:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/\"},\"wordCount\":425,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK33230&sd=2020-12-24\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/\",\"name\":\"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK33230&sd=2020-12-24\",\"datePublished\":\"2020-12-24T10:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK33230&sd=2020-12-24\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK33230&sd=2020-12-24\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/","og_locale":"en_US","og_type":"article","og_title":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk","og_description":"PR Newswire TAIPEI, Dec.\u00a024, 2020 \/PRNewswire\/ — Foresee pharmaceuticals (TPEx: 6576.TWO) (“Foresee”) announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million (NT$1.32 billion). The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee’s existing drug research and development programs \u2013 such as FP-025, for which a Phase II\/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. In addition to the progress of FP-025, Foresee’s Camcevi\u2122 42 mg, a … Continue reading \"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-24T10:03:33+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing","datePublished":"2020-12-24T10:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/"},"wordCount":425,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/","name":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24","datePublished":"2020-12-24T10:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK33230&sd=2020-12-24"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foresee-pharmaceuticals-announces-completion-of-us47-million-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405458"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405458\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}